Last reviewed · How we verify
Nifedipine/Telmisartan
This combination reduces blood pressure by blocking calcium channels (nifedipine) to relax blood vessels and blocking angiotensin II receptors (telmisartan) to prevent vasoconstriction.
This combination reduces blood pressure by blocking calcium channels (nifedipine) to relax blood vessels and blocking angiotensin II receptors (telmisartan) to prevent vasoconstriction. Used for Hypertension.
At a glance
| Generic name | Nifedipine/Telmisartan |
|---|---|
| Sponsor | Bayer |
| Drug class | Calcium channel blocker + Angiotensin II receptor blocker combination |
| Target | L-type calcium channels; AT1 angiotensin II receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nifedipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation. Telmisartan is an angiotensin II receptor blocker (ARB) that antagonizes AT1 receptors, preventing angiotensin II-mediated vasoconstriction and sodium retention. Together, they provide complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension
Common side effects
- Peripheral edema
- Headache
- Dizziness
- Flushing
- Fatigue
- Hyperkalemia
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Study Evaluating the Efficacy of Nifedipine GITS - Telmisartan Combination in Blood Pressure Control. (PHASE4)
- HIGH Altitude CArdiovascular REsearch in the ANDES (PHASE4)
- Nifedipine vs Telmisartan on Prevention of Atrial Fibrillation (AF) Recurrence in Hypertensive Patients With AF (PHASE4)
- Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nifedipine/Telmisartan CI brief — competitive landscape report
- Nifedipine/Telmisartan updates RSS · CI watch RSS
- Bayer portfolio CI